MARIANNE COSTE-BUREL

Dr. MARIANNE COSTE-BUREL


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MSMonpoeho S.
Monpoeho S.
MCMARIANNE COSTE-BUREL
MARIANNE COSTE-BUREL
CMCosta-Mattioli M.
Costa-Mattioli M.
BBBesse B.
Besse B.
CJChomel J.
Chomel J.
FVFerré V.
Ferré V.

14 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
BCBéatrice Clémenceau
Béatrice Clémenceau
TGThierry A. Guillaume
Thierry A. Guillaume
MCMARIANNE COSTE-BUREL
MARIANNE COSTE-BUREL
PPPIERRE PETERLIN
PIERRE PETERLIN
AGAlice Garnier
Alice Garnier
PCPatrice Chevallier
Patrice Chevallier
Background: At variance to humoral responses, cellular immunity after anti-SARS-CoV-2 vaccines has been poorly explored in recipients of allogeneic hematopoietic stem-cell transplantation (Allo-HSCT), especially within the first post-transplant years where immunosuppression is more profound and harmful. Methods: SARS-CoV-2 Spike protein-specific T-cell responses were explored after two doses of BNT162b2 mRNA vaccine in 45 Allo-HSCT recipients with a median time from transplant of less than 2 years by using INF-γ ELISPOT assay and flow-cytometry enumeration of CD4+ and CD8+ T lymphocytes with intracellular cytokine production of IFN-γ and TNF-α. Results: A strong TNF-α+ response from SARS-CoV-2-specific CD4+ T-cells was detected in a majority of humoral responders (89%) as well as in a consistent population of non-humoral responders (40%). Conclusions: T-cells are likely to participate in protection against COVID-19 viral infection, even in the absence of detectable antibody response, especially in the first years post-transplant in Allo-HSCT recipients.

15 March 2013 in Virology Journal
Verified
Journal Article
Open access
PDF file
VTVincent THIBAULT
Vincent THIBAULT
CGCatherine Gaudy-Graffin
Catherine Gaudy-Graffin
PCPhilippe Colson
Philippe Colson
JGJoël Gozlan
Joël Gozlan
NSNathalie Schnepf
Nathalie Schnepf
FTFrancoise Roudot Thoraval
Francoise Roudot Thoraval
Chronic hepatitis B (CHB) is a clinical concern in human immunodeficiency virus (HIV)-infected individuals due to substantial prevalence, difficulties to treat, and severe liver disease outcome. A large nationwide cross-sectional multicentre analysis of HIV-HBV co-infected patients was designed to describe and identify parameters associated with virological and clinical outcome of CHB in HIV-infected individuals with detectable HBV viremia.

1 May 2021 in Archives de Pédiatrie
Verified
Journal Article
Closed access
SMS. Marchand
S. Marchand
ELE. Launay
E. Launay
ISI. Schuffenecker
I. Schuffenecker
CGC. Gras-Le Guen
C. Gras-Le Guen
BIB.-M. Imbert-Marcille
B.-M. Imbert-Marcille
MCMARIANNE COSTE-BUREL
MARIANNE COSTE-BUREL

27 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
BCBéatrice Clémenceau
Béatrice Clémenceau
ABAmandine Le Bourgeois
Amandine Le Bourgeois
TGThierry A. Guillaume
Thierry A. Guillaume
MCMARIANNE COSTE-BUREL
MARIANNE COSTE-BUREL
PPPIERRE PETERLIN
PIERRE PETERLIN
PCPatrice Chevallier
Patrice Chevallier
A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on cellular specific immunity. Here, both B- (antibodies) and T-cell responses were explored after one (V3 n = 40) or two (V4 n = 12) BNT162b2 mRNA vaccine boosters in 52 allo-HSCT recipients at a median of 755 days post-transplant (250 BAU/mL) and anti-spike T-cell responses. Similarly, 81% of the patients developed protective antibody levels, without difference between V3 and V4 (82.5% vs. 75%, p = 0.63), and 85% displayed T-cell responses. The median frequency of anti-spike T cells did not differ either between controls or the whole cohort of patients, although it was significantly lower for V3 (but not V4) patients. COVID-19 infections were solely observed in individuals having received only one booster. These results indicate that four vaccine injections help to achieve a satisfactory level of both humoral and cellular immune protection in allo-HSCT patients.

26 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
MBMarie BOSSELUT
Marie BOSSELUT
PCPaul Carrier
Paul Carrier
SBSégolène BRICHLER
Ségolène BRICHLER
SASophie Alain
Sophie Alain
MDMarilyne Debette-Gratien
Marilyne Debette-Gratien
VLVéronique Loustaud-Ratti
Véronique Loustaud-Ratti
Hepatitis delta (HDV) infection affects 5% of hepatitis B (HBV)-positive patients, is associated with an increased risk of cirrhosis and hepatocellular carcinoma but remains underdiagnosed. The first part of our « Delta Describe » study highlighted insufficient screening of HDV patients in metropolitan France. We report here their real-world management. Patients with at least one positive HDV RNA test performed in 2019 were identified through the main French public and private laboratories. In 2024, informed patients were interviewed and physicians supplemented the collected data. 547 patients were included, median age 44 years, mainly originated from Africa or Eastern Europe. HIV and Hepatitis C coinfections were reported in 15.2% and 4.6% respectively. Liver stiffness was assessed by FibroScan® (75.3%) primarily. Most patients knew the year of diagnosis and 69% their fibrosis stage. Liver related events occurred in 14.3% of patients, mainly cirrhosis decompensation (67.9%) and hepatocellular carcinoma (28.3%). Forty-five patients underwent liver transplantation. In 2024, 47.5% had undetectable HDV RNA. Among treated patients (n=387), 37.4% received bulevirtide with or without pegylated-interferon, and 62.6% nucleos(t)ide analogues (NUCs) only. In metropolitan France, HDV patients had access to specialized follow-up, to innovative therapies (bulevirtide), were mostly on NUCs and demonstrated good disease awareness.